Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
179 studies found for:    "Haemophilus influenzae"
Show Display Options
Rank Status Study
21 Completed Immunogenicity and Safety of a Monovalent Glycoprotein-Conjugated (Diptheria Toxin -CRM197) Hib Vaccine in 13-59 Months Old Healthy Children
Condition: Haemophilus Influenzae Type b (Hib) Infection
Interventions: Biological: Monovalent glyco-conjugated vaccine against Haemophilus influenzae type b (Hib);   Biological: Tetanus toxoid polysaccharide-conjugated vaccine against Haemophilus influenzae type b (Hib)
22 Completed
Has Results
Consistency & Immunogenicity Study of 3 Lots of GSK's Hib Conjugate Vaccine Versus ActHIB & Pentacel in Healthy Infants
Condition: Haemophilus Influenzae Type b
Interventions: Biological: GSK Biologicals' Haemophilus influenzae type b vaccine (GSK 208108);   Biological: ActHIB™;   Biological: Pentacel™;   Biological: Pediarix™;   Biological: Prevnar 13™;   Biological: Rotarix™;   Biological: Engerix™-B;   Biological: Infanrix™
23 Completed Immunogenicity, Safety & Reactogenicity of GSK Vaccine Tritanrix™-HepB/Hib2.5 Compared to GSK Vaccine Tritanrix™-HepB/Hiberix™
Condition: Haemophilus Influenzae Type b
Interventions: Biological: Tritanrix™-HepB low thio /;   Biological: Hib 2.5;   Biological: Tritanrix™-HepB;   Biological: Hiberix™;   Biological: Unconjugated Hib vaccine (plain PRP)
24 Completed
Has Results
Study of Quinvaxem for Vaccination Against Diphtheria, Pertussis, Tetanus, Hepatitis B and Diseases Caused by Haemophilus Influenzae Type B
Conditions: Diphtheria;   Pertussis;   Tetanus;   Hepatitis B;   Haemophilus Influenzae Infections
Intervention: Biological: Quinvaxem
25 Completed The Immediate and Longterm Immune Responses of UK Infants and Young Children to a Booster Dose of Hib Vaccine
Condition: Haemophilus Influenzae Type b
Intervention: Biological: Hib conjugate vaccine
26 Completed Assess Safety & Reactogenicity of GSK Biologicals' Hib Vaccine Co-administered With or Without Chinese DTPw Vaccine
Condition: Haemophilus Influenzae Type b Disease
Intervention: Biological: Haemophilus Influenza type b vaccine
27 Completed A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Non-typeable Haemophilus Influenzae (NTHi) Investigational Vaccine (GSK2838497A) in Current and Former Smokers
Condition: Respiratory Disorders
Interventions: Biological: NTHI vaccine GSK2838500A (formulation 1);   Biological: NTHI vaccine GSK2838501A (formulation 2);   Biological: NTHI vaccine GSK2838502A (formulation 3);   Biological: NTHI vaccine GSK2838503A (formulation 4);   Biological: NTHI vaccine GSK2838504A (formulation 5);   Biological: NTHI vaccine GSK2838505A (formulation 6);   Biological: NTHI vaccine GSK2838508A (formulation 7);   Biological: NTHI vaccine GSK2838509A (formulation 8);   Drug: Placebo comparator
28 Completed Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Non-typeable Haemophilus Influenzae (NTHI) Vaccine
Condition: Respiratory Disorders
Interventions: Biological: GSK Biologicals' Non-Typeable H. influenzae (GSK2838500A);   Biological: GSK Biologicals' Non-Typeable H. influenzae (GSK2838501A);   Biological: Saline placebo
29 Completed
Has Results
Long-term Persistence Study to Assess a Booster Dose of GSK Biologicals' Hib-MenC
Conditions: Haemophilus Influenzae Type b;   Neisseria Meningitidis
Interventions: Biological: Haemophilus influenzae type b- and meningococcal (vaccine);   Biological: Infanrix™ penta;   Biological: Infanrix™ hexa;   Biological: Engerix-B;   Biological: NeisVac-C™;   Biological: Infanrix™ IPV/HIB;   Biological: Meningitec™
30 Completed The Safety and Immunogenicity of Haemophilus Influenzae Type b Vaccine in Different Injection Site
Condition: Healthy
Interventions: Biological: Inoculation in upper arm deltoid;   Biological: Inoculation in vastus lateralis muscle
31 Completed Immunogenicity and Safety Study of 4th LBVH0101 After the Primary Vaccination in LG-VHCL002 Study
Condition: Infectious Disease by Haemophilus Influenzae Type b
Interventions: Biological: LBVH0101 (Hib vaccine);   Biological: Hiberix™ Vaccine
32 Completed Assess the Immune Response Following Primary Vaccination With GSK Biologicals' Tritanrix™-HepB/Hib-MenAC vs Tritanrix™-HepB/Hiberix™ Given at 6,10 & 14 Wks of Age to Infants Who Received Hepatitis B Vaccine at Birth
Condition: Diphtheria; Haemophilus Influenzae Type b; Hepatitis B; Tetanus; Whole Cell Pertussis
Intervention: Biological: DTPw-HBV/Hib-MenAC conjugate vaccine
33 Completed
Has Results
Study in Toddlers to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC & to Evaluate Persistence up to 5 Years.
Conditions: Haemophilus Influenzae Type b;   Neisseria Meningitidis
Interventions: Biological: Haemophilus influenzae type b and meningococcal serogroup C (vaccine);   Biological: Priorix™;   Biological: Hiberix™;   Biological: Meningitec™
34 Completed Evaluation of Pneumococcal Vaccine Formulations in Elderly
Condition: Diseases Caused by Streptococcus Pneumoniae and Non-typable Haemophilus Influenzae, Elderly
Interventions: Biological: Pneumococcal vaccine GSK2189241A;   Biological: Pneumo 23™
35 Completed
Has Results
Study of Long-term Antibody Persistence After a Booster Dose of Menitorix Vaccine
Conditions: Haemophilus Influenzae Type b;   Neisseria Meningitidis
Interventions: Biological: Menitorix;   Biological: Infanrix IPV
36 Completed Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Pneumococcal Vaccine 2830930A Administered in Toddlers
Conditions: Haemophilus Influenzae Infections;   Streptococcus Pneumoniae Disease
Interventions: Biological: Pneumococcal vaccine GSK2830930A;   Biological: Synflorix™
37 Completed
Has Results
Persistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Meningococcal, Pneumococcal and Hib Vaccines
Conditions: Neisseria Meningitidis;   Haemophilus Influenzae Type b
Interventions: Biological: MenitorixTM;   Biological: Pneumococcal conjugate vaccine GSK1024850A;   Biological: PrevenarTM;   Biological: MeningitecTM;   Biological: NeisVac-CTM;   Biological: InfanrixTM hexa;   Biological: InfanrixTM penta;   Biological: InfanrixTM IPV/Hib;   Biological: InfanrixTM IPV
38 Completed Safety & Immunogenicity of Pneumococcal Vaccine 2189242A in Children Aged 12-23 Months at the Time of First Vaccination
Conditions: Pneumococcal Disease;   Haemophilus Influenzae Infections
Interventions: Biological: Pneumococcal vaccine GSK2189242A (formulation 1);   Biological: Pneumococcal vaccine GSK2189242A (formulation 2);   Biological: Pneumococcal vaccine GSK2189242A combined with pneumococcal vaccine GSK1024850A (formulation 3);   Biological: Pneumococcal vaccine GSK2189242A combined with pneumococcal vaccine GSK1024850A (formulation 4);   Biological: Pneumococcal vaccine GSK1024850A
39 Completed Immunogenicity and Safety of A Group A, C Polysaccharide Meningococcal and Type b Haemophilus Influenzal Conjugate Vaccine in Infants and Children
Conditions: Group A, C Polysaccharide Meningitis;   Type b Haemophilus Influenza
Interventions: Biological: A+C+hib Conjugate Vaccine;   Biological: Placebo;   Biological: A+C Vaccine;   Biological: Hib vaccine
40 Completed
Has Results
Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age.
Conditions: Haemophilus Influenzae Type b;   Neisseria Meningitidis
Interventions: Biological: GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined (792014);   Biological: PedvaxHIB;   Biological: Prevnar;   Biological: M-M-R II;   Biological: Varivax

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.